You just read:

OliX Pharmaceuticals receives Clinical Trial Authorization in the UK to initiate Phase I study with OLX10010, an anti-scar RNAi therapeutics

News provided by

OliX Pharmaceuticals, Inc.

29 May, 2018, 09:12 BST